Gurjaipal Kang

CURRICULUM VITAE Gurjaipal (Paul) Singh Kang MD FACC FACP FSCAI DOB: September 1, 1968 Citizenship: United States Address: 4368 Winners Circle Erie, PA 16506 Telephone: 814 833-4446 Fax No: 814 833-2281 Education and Employment 3/2007-Present: Director of Cardiac Catheterization Laboratory – Hamot Medical Center 1/2003-Present: Director of Invasive Cardiac Services—Meadville Medical Center 7/2001-Present: Hamot Medical Center : Intervention/Cardiovascular Disease 7/2001-Present: Medicor Associates, Inc., 120 East Second Street, Erie, PA 16507 Partner 7/2004 7/2000-6/2001: Interventional Cardiology fellow at University Hospitals of Cleveland/Case Western Reserve University 7/1999-6/2000: Assistant Professor of Medicine/Cardiology at Temple University, Philadelphia. Attending Physician/Cardiologist at Temple University Hospital, Philadelphia, PA. (Very active in cardiac catheterization, echocardiography, coronary care unit and clinical cardiology). 7/1999-6/1999: Chief Fellow, Cardiovascular Diseases, Case Western Reserve University/University Hospitals of Cleveland. 7/1997-6/1998: Fellow, Cardiovascular Diseases, Case Western Reserve University/Univ. Hospitals of Cleveland. 7/1996-6/1997: Fellow, Cardiovascular Diseases, Mt. Sinai School of Medicine, Elmhurst Hospital Program. 7/1995-6/1996: Chief Resident, Loma Linda University School of Medicine Internal Medicine Residency Program. 7/1995-6/1996: Attending Physician Riverside General Hospital/Instructor-Loma Linda University School of Medicine. 7/1993-6/1995: Resident, Internal Medicine Loma Linda University Medical Center 7/1992-6/1993: Resident, Internal Medicine Albert Einstein University/Flushing Hospital Program 8/1986-1/1992: Medical Student Government Medical College, Amritsar, Punjab, India 6/1984-6/1986: Pre-Medical Student Khalsa College, Amritsar, Punjab, India. 1/1973-4/1984: Student, St. Francis School, Amritsar, Punjab, India. Board Certified In: 2009: Board recertification in echocardiography 92% 2009: Board certified in Endovascular and Vascular Medicine. ABVM diplomat. 2009: Recertification in Cardiovascular medicine boards – Decile 10 Recertification in Nuclear Cardiology and Interventional Cardiology examination 2007: Cardiac CT Level II Certificate 2005: Re-certification-Internal Medicine Boards Decile 10 2001: American Board of Internal Medicine: Interventional Cardiology 1999: American Board of Internal Medicine: Examination Percentage: Overall 87%. Decile 10. EKG component 89%: Cardiovascular Disease 1999: Certification Board of Nuclear Cardiology. Percentage: Overall 89%: Nuclear Cardiology. Gurjaipal S. Kang, M.D. Page 2 1999: National Board of Echocardiography. Percentile 92% - Adult Comprehensive Echocardiography. 1995: American Board of Internal Medicine. Deciles 9 & 8: Internal Medicine. 1995: Internal Medicine Intraining Examination. Percentile 97% plus. 1992: FMGEMs examinations. Scores 87 & 85. Research: Peer Reviewed Publications: 2011: EuroIntervention Journal (European Association of Percutaneous Cardiovascular Interventions (EAPCI)) Abstract published on Excellent Femoral results with Perclose for oral presentation in EuroPCR 2011 2007: American Journal of Emergency Medicine, SVG Aneurysm leading to tamponade- Kang, G, et al. 2006: American Journal of Emergency Medicine, Spontaneous Coronary Dissection, Kang, G, et al. 2006: Southern Medical Journal, Tamponade in Thyroid Disease, Ashvath M., Kang, G, et al. 2005: American Journal of Geriatric Cardiology, New Diagnosis of Left Atrial Myxoma in a 93 Cardiology-Kang GS, Sanchez B, Kang MK, Hansen C: Effect of exercise induced hypertension on left ventricular hypertrophy in normotensive individuals. Presentations in Major International Meetings: CRT 2012, Washington DC. Results in Femoral Artery practice with only board certified cardiologists doing the stick. Accepted for poster presentation. Euro PCR 2011, Paris France. Excellent results from Perclose technology compared to Radial approach ORAL PRESENTATION. ICCAD 2009: Poster Presentation: International Congress of Coronary Artery Disease Prague Czech Republic. A very large perclose experience with no infections Fortis Hospital International Global Conference 2011 Session Moderator. Guest Speaker. 2000: Poster presentation-Pennsylvania Chapter of American College of Cardiology-Kang GS, Zheng JS, Kang MK, Rothman S, Thames MD: Usefulness of D-Dimer testing in evaluation of left atrial thrombi. 1995: International Heart Failure in Geneva, Switzerland-Engel G, Kang GS, Sweeney M et al: Significant improvements in LV systolic function possible in patients attending a cardiomyopathy clinic. 1995: Loma Linda University Annual Meeting Honoring Research-Engel G, Kang GS, Sweeney M et al: Significant improvements in systolic function possible in patients attending a cardiomyopathy clinic. Completed abstracts pending submission: 2000: Kang GS, Rothman S, Hansen C et al: Effect of exercise induced hypertension on left ventricular hypertrophy in normotensive individuals. 2000: Pending resubmission to American Association of Medical Colleges (RIME conference)- Kang GS, Loo L, Bouland D: Improvement in documentation due to an introduction of a peer review conference in the residents’ monthly schedule. Completed manuscripts pending submission: 2000: CHEST journal-Kang GS, Farah MG: Early diagnosis of aortic abscess using transesophageal echocardiography. Research Awards: 1995: Presenter of the winning abstract in Loma Linda University Annual Meeting Honoring Research- Engel G, Kang GS, Sweeney M et al: Improvements in LV systolic function possible in patients attending a cardiomyopathy clinic. 1993: Certificate of Merit from Flushing Hospital Medical Center for a very high number of patient enrollment in Digoxin Investigation group trial. Gurjaipal S. Kang, M.D. Page 3 Other Research Experience: 2011: Primary Investigator Dalcetrapib outcomes large randomized trial-multi center. 2009-ongoing Sub-Investigator – Carotid Stenting for High Surgical Risk Patients; Evaluating Outcomes through the collection of Clinical Evidence (“CHOICE”) 2009-ongoing Primary Investigator - APPRAISE-2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome 2009 Sub-Investigator – A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention with the ENDEAVOR Zatoralimus-eluting Coronary Stent (CYPHER ® Stent) 2009. Primary Investigator – The PROTECT Continued Access Post Marketing Surveillance Trial 2008-ongoing Sub-Investigator-A Prospective, Non-Randomized, Two Arm Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of the Absolute Pro ™ Peripheral Self-Expanding Stent System and The Omnilink Elite ™ Peripheral Balloon-Expandable Stent System in Subjects with Atherosclerotic DE NOVO or Restenotic Lesions in the Native Common Iliac Artery And/or Native External Iliac 2008-Ongoing Principal Investigator-A Multi-center, Randomized, Double-Blind, Placebo – Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in addition to standard of care in subjects with Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA-CER) 2009. Sub-Investigator-Variation in Recovery: Role of Gender on Outcomes in Acute Myocardial Infarction (AMI) Patients (VIRGO) 2008 Sub-Investigator – XIENCE V™ Everolimus Eluting Coronary Stent System (EECSS) EXCEED: Evaluation of XIENCE V™ for Catheterization Lab Endpoints a2009. Sub-Investigator – CAPTURE 2 A post-approval Study of the Guidant acculink stent Systems and accunet embolic protection systems, Carotid RX ACCULINK/ to Uncover Unanticipated and Rare Events 2005-2006 Primary Investigator – The ACUITY Trial: A randomized comparison of Angiomax ® (bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients under going early invasive management for acute coronary syndromes without ST-segment elevation 2006. Primary Investigator – APEX – A Multicenter, Randomized, Double-Blind, Parallel- Group, Placebo-Controlled Study of Pexelizumab in patients with Acute Myocardial Infarction undergoing Primary Percutaneious Coronary Intervention 2000. Principal Investigator -Schering Plough Multicenter trial- To evaluate the safety and Efficacy of SCH 58235: Phase III Double-Blind Efficacy and Safety study of a new Antilipid agent Collecting prospective data on Discomfort during cardiac catheterization (DOC) study 1998. Obtained Institutional Review Board approval as the Chief Investigator in a trial to Evaluate hemodynamics of Medtronic stentless valve in aortic position. 1998. Applied for ACC/Merck fellowship award and AHA affiliate in training award for role Of impaired sensitivity of cardiopulmonary and aortic baroreceptors in rapid pacing Induced model of heart failure. 1994. Evaluated role of E Wave to reverse E Wave transit time in impaired relaxation in LVH. Gurjaipal S. Kang, M.D. Page 4 Invited Lectures: CME accredited lectures: 2000-2005: Multiple Cardiology Grand Rounds at Hamot Medical Center. 1999: Scientific Exchange Incorporation (Connecticut) sponsored lectures on Clinical paradigms in management of atherosclerosis: in Albany and Houston. 1998-1999: Full series of lectures to cardiology faculty and fellows in Case Western Reserve University to cover topics of American Society of Echocardiography examination. 1996-1998: Grand round presentations in Case Western Reserve University/University Hospitals of Cleveland. Grand Rounds in Elmhurst Hospital, NY. 1998-1999: Presented an average of one lecture per week during the chief cardiology fellowship. Superior evaluation by housestaff for conference presentations. 1999-2000: Bristol Myers Squib and Merck sponsored lectures to cardiology and medicine house staff on hypercholesterolemia, inflammatory mediators of coronary artery disease, role of ace- inhibitors and angiotensin receptor blockers in heart failure. 1998: Lectures as a part of teaching curriculum of 2nd year medical students at Loma Linda University and Case Western Reserve University. 1995-1996: An average of one lecture per week to medicine house staff and 3rd and 4th year medical students as Chief Resident at Loma Linda University. Awards and Honors: 2011: Fortis Hospital India Global Conference award for Speaker/Session Moderator 2009: TRACER trial award for very high enrollment in a randomized trial 7/1998-6/1999: Chief Fellow in Cardiology-Case Western Reserve University/University Hospitals of Cleveland. 7/1995-6/1996: Chief Resident in Internal Medicine-Loma Linda University Internal Medicine Program. 1995: Presented the Winning abstract in the Loma Linda University Annual Meeting Honoring Research. 1995: Scored above the national percentile scale, 97 percentile plus in National Intraining Examination of the American Board of Internal Medicine. 1994-1995: Awards for top scores in the core curriculum examinations in Loma Linda University Residency program. 1995: Recipient of second highest votes for the outstanding resident of the year from other residents and faculty at Loma Linda University and three affiliated hospitals. 1995: 90% score in Department of Health Services Examination, California. 1986: Position 171986: Governor’s invitation for academic achievement in Punjab, India. 1986: Placed in Khalsa College Merit List for academic achievements. 1984: Gold Medal and First Position in ICSE (Indian Certificate of Secondary Education Examinations) First position in class from third grade up to graduation during high school & elementary school education. Licensure and Certification: Licensed in: Pennsylvania: Expiration date 12/31/10 Ohio: Expiration date 10/01/10 New York: Expiration date 08/31/11 California: Expiration date 09/30/11 Gurjaipal (Paul)Singh Kang M.D Page 5 Professional Fellowships: Fellow of American College of Cardiology Fellow of American College of Physicians Fellow of Society of Coronary angiography and interventions. Interests and Hobbies: Runners up in Table Tennis in National Medical College Games in New Delhi, India, 1988 College Colors (highest honors for sports achievement in Govt. Medical College), 1991 Member of College soccer, table tennis and track teams. Community Work Free Vascular Screenings offered to public in the Erie, PA mall and other settings.